Predicting Response to Platinum Chemotherapy in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Using a Genomic Signature for "BRCAness," A Phase II Prospective Open Label Clinical Trial of Second Line Satraplatin in Men with mCRPC
ID Number 10-1222Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study is to test genes, which are materials that are passed from parent to child that may have changed within the tumor. Studying these genes could help predict which patients would benefit from treatment with satraplatin, a medication being used for those who failed prior chemotherapy. The researchers are interested in satraplatin because it has been tested in a large number of men with metastatic prostate cancer who have failed a prior chemotherapy. In study involving almost one thousand men treated with satraplatin or a placebo (sugar pill), patients treated with satraplatin experienced less pain and were free from cancer progression for a longer period of time as compared to patients that did not receive satraplatin. This medication was not approved by the Food and Drug Administration (FDA) because the study did not find a difference in survival. We are interested in being able to identify genes that predict response to satraplatin in order to develop a tool (gene signature) to be able to pre-screen patients who will likely benefit from satraplatin.
Recruiting Patients: Yes